NCT06069206View on ClinicalTrials.gov

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

NACompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

December 14, 2024

Study Completion Date

April 22, 2025

Conditions
Bloodstream InfectionSepsis BacterialMRSA BacteremiaVancomycin
Interventions
OTHER

T2Bacteria® Panel (direct-from-blood testing)

Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.

OTHER

Usual Care

Standard blood cultures.

Trial Locations (1)

37203

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes | Biotech Hunter | Biotech Hunter